Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Arq. bras. cardiol ; 113(3): 345-354, Sept. 2019. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1038542

RESUMEN

Abstract Background: Brazil has approximately 30.000 cases of Acute Rheumatic Fever (ARF) annually. A third of cardiovascular surgeries performed in the country are due to the sequelae of rheumatic heart disease (RHD), which is an important public health problem. Objectives: to analyze the historical series of mortality rates and disease costs, projecting future trends to offer new data that may justify the need to implement a public health program for RF. Methods: we performed a cross-sectional study with a time series analysis based on data from the Hospital Information System of Brazil from 1998 to 2016. Simple linear regression models and Holt's Exponential Smoothing Method were used to model the behavior of the series and to do forecasts. The results of the tests with a value of p < 0.05 were considered statistically significant. Results: each year, the number of deaths due to RHD increased by an average of 16.94 units and the mortality rate from ARF increased by 215%. There was a 264% increase in hospitalization expenses for RHD and RHD mortality rates increased 42.5% (p-value < 0.05). The estimated mortality rates for ARF and RHD were, respectively, 2.68 and 8.53 for 2019. The estimated cost for RHD in 2019 was US$ 26.715.897,70. Conclusions: according to the Brazilian reality, the 1-year RHD expenses would be sufficient for secondary prophylaxis (considering a Benzatin Penicillin G dose every 3 weeks) in 22.574 people for 10 years. This study corroborates the need for public health policies aimed at RHD.


Resumo Fundamento: O Brasil tem aproximadamente 30.000 casos de febre reumática aguda (FRA) por ano. Um terço das cirurgias cardiovasculares realizadas no país se deve às sequelas da doença reumática cardíaca (DRC), a qual é um importante problema de saúde pública. Objetivos: Analisar as séries históricas de taxas de mortalidade e custos das doenças, projetando tendências futuras para oferecer novos dados que possam justificar a necessidade de implementação de um programa de saúde pública para FR. Métodos: Foi realizado um estudo transversal com análise de séries temporais a partir de dados do Sistema de Informações Hospitalares do Brasil, de 1998 a 2016. Modelos de regressão linear simples e o método de suavização exponencial de Holt foram utilizados para modelar o comportamento das séries e fazer previsões. Os resultados dos testes com um valor de p <0,05 foram considerados estatisticamente significantes. Resultados: A cada ano, o número de mortes por DRC aumentou em média 16,94 unidades, e a taxa de mortalidade por FRA aumentou em 215%. Houve um aumento de 264% nas despesas de hospitalização por DRC, e as taxas de mortalidade por DRC aumentaram 42,5% (p-valor < 0,05). As taxas de mortalidade estimadas para FRA e DRC foram, respectivamente, 2,68 e 8,53 para 2019. O custo estimado para a DRC em 2019 foi de US$ 26.715.897,70. Conclusões: De acordo com a realidade brasileira, o gasto relativo a 1 ano de DRC seria suficiente para a profilaxia secundária (considerando uma dose de penicilina G benzatina a cada 3 semanas) em 22.574 pessoas por 10 anos. Este estudo corrobora a necessidade de políticas públicas de saúde direcionadas à DRC.


Asunto(s)
Humanos , Cardiopatía Reumática/prevención & control , Cardiopatía Reumática/economía , Cardiopatía Reumática/mortalidad , Brasil/epidemiología , Modelos Lineales , Estudios Transversales , Mortalidad , Prevención Secundaria , Hospitalización
3.
Indian J Pediatr ; 2007 Jun; 74(6): 567-70
Artículo en Inglés | IMSEAR | ID: sea-83346

RESUMEN

OBJECTIVE: To measure the economic output/input ratios for the various options of prevention of rheumatic fever/rheumatic heart disease (RF/RHD) and check the viability of primary prevention vis-à-vis secondary and tertiary preventions. METHODS: Cost accounting of the various prevention options was calculated for each variable as available in literature. Actual data as obtainable for the financial year ending March 2006 were computed for the Pondicherry population. Both direct and indirect costs (including community/social costs) were worked out using mostly primary data and wherever necessary, secondary data. Certain scientific assumptions were used where exact data was not available. RESULTS: Primary prevention is the definite viable economic option (1:1.56) compared to secondary (1: 1.07) and tertiary (1: 0.12) preventions. In fact, the current stress on only secondary and tertiary preventions is found to be economically unviable. CONCLUSION: It is postulated that primary prevention as a practical policy in tackling RF and RHD can be recommended.


Asunto(s)
Niño , Preescolar , Ahorro de Costo , Análisis Costo-Beneficio , Países en Desarrollo , Femenino , Costos de la Atención en Salud , Humanos , India , Masculino , Prevención Primaria/economía , Fiebre Reumática/economía , Cardiopatía Reumática/economía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA